Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries

Name	World Continuing Education Alliance
Activity Title	Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries
Details	is also known as Lancefield’s group B. Neonatal infections (sepsis and pneumonia) contribute importantly to deaths among children under 5 years of age globally, with the highest rates in low income countries, followed by middle income countries. Among various vaccine candidates, the glycoconjugate vaccines targeting GBS capsular polysaccharide (CPS) have been most studied, although common protein vaccines hold the appeal of broader coverage against circulating disease-causing strains. GBS vaccine development underwent an active phase in the 1990s. Although pre-clinical and early clinical studies showed promise, efforts slowed for a period, for a variety of reasons, including the strong success of intrapartum prophylaxis in reducing the early-onset disease burden in high income countries, and concerns about the acceptance and the liability coverages for maternal immunization. Recent years have experienced a wave of new activity in GBS vaccine development. Successes in rolling out pneumo...
Competence	Public Health
Start Date	<span class="not-set">(not set)</span>
End Date	<span class="not-set">(not set)</span>
Event Time	11:30 AM
Location	World Continuing Education Alliance eLearning System
Cost (UGX)	0
CPD Points	1